A personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.
Nancy Y. Lee, MD
Advertisement
Articles by Nancy Y. Lee, MD
Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the combination of a PD-L1 inhibitor to the standard of care for patients with head and neck cancer.
Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.
Advertisement
Latest Updated Articles
Dr. Lee on the Impact of Immunotherapy in Head and Neck CancerPublished: June 14th 2017 | Updated:
Dr. Lee on Combining Anti-PD-L1 to Standard of Care for Head and Neck CancerPublished: June 20th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5